Background: Cutaneous leishmaniasis is an endemic disease in developing countries. The first-line drugs for its treatment are the pentavalent antimony compounds such as meglumine antimoniate (MA). High cost, side effects, multiple injections and incomplete efficacy are limitations of this therapy. Zinc sulfate (ZS) has been reported to be effective in the treatment of cutaneous leishmaniasis. Objective: To compare the efficacy of intralesional injections of ZS 2% with those of MA in the treatment of cutaneous leishmaniasis. Methods: This was a prospective, double-blind, case-control clinical study. 104 patients with typical lesions of acute cutaneous leishmaniasis (ACL) were included. The duration of treatment was 6 weeks. Improvement was evaluated by clinical examination and direct smear. Results: The study was completed in only 66 patients: 35 patients received MA and 31 received ZS. The cure rates were 60% for MA and 83.8% for ZS. After the second and fourth weeks, the efficacy of treatment with ZS was higher than that with MA (p < 0.01), but after 6 weeks no significant differences were observed between the two groups (p > 0.05). Conclusion: On the basis of this trial and despite the high number of drop-outs, we consider that the intralesional injection of ZS 2% is an alternative treatment in ACL.

Keywords:
Cutaneous leishmaniasis, Zinc sulfate, Pentavalent antimony compounds
1.
Pearson RD, De Queiroz Sousu A, Jeronimo SMB: Leishmania species: Visceral (kala-azar), cutaneous and mucosal leishmaniasis; in Mnadell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases, ed 5. Philadelphia, Churchill Livingstone, 2000, pp 2831–2833.
2.
Bryceson ADM, Hay RJ: Parasitic worms and protozoa; in Champion RH, Burton JL, Burns DA, Breathnach SM (eds): Rook Textbook of Dermatology, ed 6. London, Blackwell Science, 1988, pp 1411–1412.
3.
Goldsmith RS: Antiprotozoal drugs; in Katzung BG (ed): Basic and Clinical Pharmacology, ed 7. London, Asimon & Schuster, 1998, pp 854–855.
4.
Lerner EA, Grevelink SA: Leishmaniasis; in Arnd KA, LeBoit PE, Robinson JK, Wintroub BU (eds): Cutaneous Medicine and Surgery, ed 1. Philadelphia, Saunders & Co, 1996, pp 1163–1171.
5.
Oslen RE, Berdanier CD: Microminerals; in Munson PH, Mueller RA, Breese GR (eds): Principles of Pharmacology, ed 1. New York, Chapman & Hall, 1994, pp 1002–1005.
6.
Sharquie KE, Najim RA, Farjou IB: A comparative controlled trial of intralesionally administered zinc sulfate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol 1997;22:169–173.
7.
Sharquie KE, Al Talib KR, Chu AC: Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988;119:53–57.
8.
Gurei MS, Tatli N, Ozbilge H, et al: Efficacy of cryotherapy and intralesional Pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 2000;30:169–176.
9.
Uzun S, Uslular C, Yucel A, Acar MA, Ozpoyraz M, Memisoglu HR: Cutaneous leishmaniasis: Evaluation of 3,074 cases in the Cukurova region of Turkey. Br J Dermatol 1999;140:347–350.
10.
Launois P, Conceicao Silva F, Himmerlich H, Parra Lopez C, Tachini Cottier F, Louis JA: Setting in motion the immune mechanisms underlying genetically determined resistance and susceptibility to infection with Leishmania major. Parasite Immunol 1998;20:223–230.
11.
Najim RA, Sharquie KE, Farjou IB: Zinc sulphate in the treatment of cutaneous leishmaniasis: An in vitro and animal study. Mem Inst Oswaldo Cruz 1998;93:831–837.
12.
Momeni AZ, Jalayer T, Emamjomeh M, et al: Treatment of cutaneous leishmaniasis with itraconazole. Arch Dermatol 1996;132:784–786.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.